Mary T Huber

Title: Mary T Huber: Innovator in Anti-CMV Drug Development

Introduction

Mary T Huber is a notable inventor based in Portland, OR (US). She has made significant contributions to the field of medical research, particularly in the development of anti-CMV drugs. With a total of 2 patents, her work focuses on innovative solutions to combat cytomegalovirus (CMV) infections.

Latest Patents

Mary T Huber's latest patents include a groundbreaking method involving human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate. This invention outlines a method for designing a new anti-CMV drug, which includes analyzing the binding of glycoprotein O to its receptor. The process involves designing a candidate drug that would competitively interfere with this binding, demonstrating that the candidate drug effectively inhibits glycoprotein O binding to its receptor. Additionally, the patent discloses methods for screening anti-CMV drugs, developing a vaccine to diminish CMV infection, and strategies for reducing CMV infection.

Career Highlights

Mary T Huber is associated with the Wisconsin Alumni Research Foundation, where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of CMV and exploring new therapeutic avenues.

Collaborations

Mary collaborates with Teresa Compton, who is also a prominent figure in the field. Together, they work on innovative projects aimed at addressing the challenges posed by CMV infections.

Conclusion

Mary T Huber's contributions to the field of anti-CMV drug development highlight her innovative spirit and dedication to medical research. Her patents represent significant advancements in the fight against viral infections, showcasing her role as a leading inventor in this critical area.